{"id":959,"date":"2026-05-25T03:50:11","date_gmt":"2026-05-25T03:50:11","guid":{"rendered":"https:\/\/wuhantopmiraclepeptides.com\/?post_type=product&p=959"},"modified":"2026-06-11T06:32:46","modified_gmt":"2026-06-11T06:32:46","slug":"tesamorelin-cjc-1295-ipamorelin-blend-12mg","status":"publish","type":"product","link":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/product\/tesamorelin-cjc-1295-ipamorelin-blend-12mg\/","title":{"rendered":"Tesamorelin & CJC-1295 & Ipamorelin Blend 12mg"},"content":{"rendered":"

Tesamorelin & CJC-1295 & Ipamorelin Blend 12mg: A Tripartite Tool for Growth Hormone Research<\/span><\/h1>\n

If your laboratory investigates the intricate interplay of growth hormone (GH) signalling, metabolism, and tissue repair, the Tesamorelin & CJC-1295 & Ipamorelin Blend 12mg <\/span>offers a uniquely comprehensive platform. <\/span><\/p>\n

This formulation combines three well-characterised growth hormone secretagogues\u2014Tesamorelin (a GHRH analogue), CJC-1295 (a long-acting GHRH derivative), and Ipamorelin (a selective ghrelin receptor agonist)\u2014each acting through distinct, synergistic pathways to modulate the hypothalamic-pituitary-somatotropic axis. This multi-pathway approach allows researchers to model GH pulsatility, assess metabolic outcomes, and study tissue regeneration with a level of precision that single-agent studies cannot achieve.<\/span><\/p>\n

At Wuhan Top Miracle Peptides, we supply this research-grade Tesamorelin & CJC-1295 & Ipamorelin Blend 12mg<\/span> \u00a0to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA.<\/span><\/p>\n

Every batch is manufactured using solid-phase peptide synthesis (SPPS), purified by preparative high-performance liquid chromatography (HPLC), and validated by mass spectrometry to meet rigorous quality standards. Each shipment includes a Certificate of Analysis (COA) confirming \u226599% purity, ensuring your studies into GH regulation, body composition, or recovery are built on a foundation of uncompromising quality.<\/span><\/p>\n

What Makes This Triple-Action Blend a Unique Research Tool?<\/span><\/h2>\n

The\u00a0<\/span>Tesamorelin & CJC-1295 & Ipamorelin Blend 12mg<\/span><\/strong>\u00a0is more than the sum of its parts. Each component targets a specific node in the GH regulatory network, creating a multi-faceted research model that more closely mirrors the complexity of endogenous GH physiology.<\/span><\/p>\n

The Three Complementary Mechanisms of Action<\/span><\/h3>\n
    \n
  • \n

    Tesamorelin: The Clinically Validated GHRH Agonist.<\/span><\/strong>\u00a0Tesamorelin is a synthetic 44-amino acid polypeptide analogue of endogenous growth hormone-releasing hormone (GHRH), modified at its N-terminus for enhanced stability and resistance to enzymatic breakdown<\/span>. It binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH) with a potency similar to the natural hormone<\/span>. This activation leads to an increase in insulin-like growth factor 1 (IGF-1), which mediates many of GH’s downstream anabolic and lipolytic effects<\/span>. <\/span>In 2010, Tesamorelin received FDA approval for reducing excess visceral fat in HIV-associated lipodystrophy, supported by two pivotal Phase 3 trials showing an average 18% reduction in visceral adipose tissue at 26 weeks<\/span>.<\/span><\/p>\n<\/li>\n

  • \n

    CJC-1295: The Long-Acting GHRH Analogue.<\/span><\/strong>\u00a0CJC-1295 is a synthetic derivative of GHRH containing four amino acid substitutions that enhance its activity and protect it from proteolytic degradation<\/span>. This tetrasubstituted form of hGRF(1-29) possesses an extended plasma half-life, enabling a prolonged and sustained stimulation of GH secretion and elevated IGF-1 levels compared to the native hormone<\/span>. Notably, the version used in this blend is CJC-1295\u00a0<\/span>without<\/span><\/strong>\u00a0the Drug Affinity Complex (DAC). <\/span>While the DAC-conjugated form can have a half-life of up to 8 days with measurable levels for 10-13 days, the non\u2011DAC version has a shorter half-life<\/span>. This makes it more suitable for research that aims to mimic the body’s natural, pulsatile GH rhythm, offering a more physiological research model<\/span>.<\/span><\/p>\n<\/li>\n

  • \n

    Ipamorelin: The Selective Ghrelin Receptor Agonist.<\/span><\/strong>\u00a0Ipamorelin is a synthetic pentapeptide that acts as a highly selective agonist of the ghrelin\/growth hormone secretagogue receptor (GHS-R1a)<\/span>. It was first described in a 1998 paper in the\u00a0<\/span>European Journal of Endocrinology<\/span><\/em>\u00a0as “the first selective growth hormone secretagogue”<\/span>. In vitro, Ipamorelin releases GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6<\/span>. <\/span>Its key research advantage is its remarkable selectivity: unlike older GHRPs, Ipamorelin stimulates GH release without significantly elevating cortisol, adrenocorticotropic hormone (ACTH), or prolactin levels, even at doses more than 200-fold higher than the ED\u2085\u2080 for GH release<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n

    The Scientific Rationale for a Triple Combination<\/span><\/h2>\n

    The rationale behind combining these three peptides is rooted in the complex, dual-pathway control of GH secretion. GH release from the pituitary is primarily driven by the interaction of two hormones from the hypothalamus: stimulatory GHRH and inhibitory somatostatin. The\u00a0<\/span>Tesamorelin & CJC-1295 & Ipamorelin Blend 12mg<\/span><\/strong>\u00a0employs a more comprehensive, multi-pathway approach that may offer distinct advantages over single-agent experiments:<\/span><\/p>\n